RCAMU
AMED

Rothschild & Co Asset Management US’s Amedisys AMED Stock Holding History

Rothschild & Co Asset Management US’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-31,964
Closed -$5.51M – 265
2022
Q1 		$5.51M Sell
31,964
-9,262
-22% -$1.38M 0.07% 194
2021
Q4 		$6.67M Buy
41,226
+6,739
+20% +$1.08M 0.08% 203
2021
Q3 		$5.14M Sell
34,487
-2,706
-7% -$563K 0.06% 218
2021
Q2 		$9.11M Sell
37,193
-4,220
-10% -$1.11M 0.11% 198
2021
Q1 		$11M Sell
41,413
-18,632
-31% -$5.25M 0.14% 187
2020
Q4 		$17.6M Sell
60,045
-13,289
-18% -$3.41M 0.23% 152
2020
Q3 		$17.3M Sell
73,334
-15,608
-18% -$3.55M 0.31% 137
2020
Q2 		$17.7M Sell
88,942
-141,193
-61% -$26.3M 0.26% 164
2020
Q1 		$42.2M Sell
230,135
-37,517
-14% -$6.67M 0.66% 37
2019
Q4 		$44.7M Sell
267,652
-44,282
-14% -$6.59M 0.46% 68
2019
Q3 		$40.9M Sell
311,934
-27,266
-8% -$3.55M 0.44% 75
2019
Q2 		$41.2M Sell
339,200
-25,310
-7% -$3M 0.44% 76
2019
Q1 		$44.9M Buy
364,510
+622
+0.2% +$78.1K 0.48% 62
2018
Q4 		$42.6M Sell
363,888
-65,171
-15% -$7.68M 0.51% 51
2018
Q3 		$53.6M Sell
429,059
-18,203
-4% -$2.01M 0.55% 46
2018
Q2 		$38.2M Buy
447,262
+1,278
+0.3% +$93.8K 0.41% 86
2018
Q1 		$26.9M Sell
445,984
-6,542
-1% -$373K 0.3% 148
2017
Q4 		$23.9M Sell
452,526
-16,201
-3% -$854K 0.25% 169
2017
Q3 		$26.2M Buy
468,727
+27,816
+6% +$1.47M 0.29% 148
2017
Q2 		$27.7M Buy
440,911
+14,440
+3% +$841K 0.31% 117
2017
Q1 		$21.8M Buy
426,471
+15,150
+4% +$723K 0.25% 157
2016
Q4 		$17.5M Buy
411,321
+65,571
+19% +$2.79M 0.22% 177
2016
Q3 		$16.4M Sell
345,750
-3,910
-1% -$195K 0.28% 149
2016
Q2 		$17.7M Buy
349,660
+31,434
+10% +$1.59M 0.32% 111
2016
Q1 		$15.4M Buy
318,226
+52,578
+20% +$2.03M 0.29% 111
2015
Q4 		$10.4M Buy
+265,648
New +$10.6M 0.19% 177

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rothschild & Co Asset Management US's AMED Position: Q2 2022 in Review

Rothschild & Co Asset Management US sold out of Amedisys (AMED) in Q2 2022, closing a stake of 31,964 shares — an estimated $5.51M sold.

Rothschild & Co Asset Management US first reported a position in AMED in Q4 2015 and held it in 26 quarters. The position peaked at $53.6M in Q3 2018. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

  • Rothschild & Co Asset Management US reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 31,964 Amedisys shares in Q2 2022, an estimated $5.51M.
  • Rothschild & Co Asset Management US first reported a position in Amedisys in Q4 2015 and held it in 26 quarters.
  • Rothschild & Co Asset Management US's Amedisys position peaked at $53.6M in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q2 2022, filed 9 Aug 2022.